TY - JOUR T1 - Serogroup C invasive meningococcal disease in the post-vaccine era and vaccine failures JO - Anales de Pediatría (English Edition) T2 - AU - Rius,Neus AU - Lung,Mayli AU - Fernández-San José,Carolina AU - Iglesias,Tamara AU - Esperalba,Juliana AU - Moraga-Llop,Fernado A. AU - Soler-Palacín,Pere SN - 23412879 M3 - 10.1016/j.anpede.2020.02.005 DO - 10.1016/j.anpede.2020.02.005 UR - https://analesdepediatria.org/en-serogroup-c-invasive-meningococcal-disease-articulo-S234128792030199X AB - IntroductionThe incidence of serogroup C invasive meningococcal disease (IMD) has decreased since the introduction of systematic vaccination in 2000 The aim of this study is to determine the number serogroup C IMD cases diagnosed since then and the vaccine failures. Patients and methodsA retrospective analysis was performed on patients diagnosed with IMD by culture or polymerase chain reaction (PCR) in a maternity and childhood hospital in Barcelona between 2001 and 2018. An analysis was made of the number of vaccine doses and the age received, as well as on the medical records and vaccine cards. ResultsThere were 128 confirmed cases of IMD (7.1 cases/year; 70.3 in <5 years). The serogroup was studied in 125 (97.6%) cases, in which 103 (82.4%) were B, 10 (8%) were C, 1 (0.8%) was 29E, and 1(0.8%) was Y, and only 10 (8%) were not able to be serogrouped. Of the 10 patients with serogroup C, 4 were not vaccinated, and in 3, the course was not complete as regards the number of doses. The other 3 received the complete course according to age and current calendar, and thus were considered vaccine failures. A total of 6 patients died (mortality rate: 4.7%), 5 due to serogroup B (mortality: 4.8%), and 1 due to serogroup C (mortality: 10%). ConclusionsSerogroup C only represented 8% (10 cases) of IMD cases in the period studied, 3 cases due to this serogroup being vaccine failures. ER -